文献速递围术期管理与 ERAS胃肠外科

预防性胰岛素在非糖尿病手术患者中的应用:一项预试验随机对照试验

The Use of Prophylactic Insulin in Surgical Patients Without Diabetes: A Pilot Randomized, Controlled Trial.
PubMed 文献 · Ann Surg · 2026-06-18

该预试验随机对照试验在非糖尿病腹部盆腔大手术患者中比较预防性葡萄糖-胰岛素-钾(GIK)与安慰剂,评估可行性与临床结局。共随机103例,GIK组围术期正常血糖更常见、高血糖及治疗性胰岛素使用更少,并发症有减少趋势但置信区间宽。

要点

  • GIK方案可行,97%完成治疗且无严重低血糖事件。
  • GIK组围术期正常血糖(<125 mg/dL)比例更高(42% vs 27%,P<0.01)。
  • GIK组高血糖及治疗性胰岛素使用更少,并发症有减少趋势但置信区间宽。

核心结论

  • 预防性胰岛素可改善非糖尿病手术患者的血糖结局,并可能通过抗炎机制改善临床结局。
  • 开展以并发症/死亡率为终点的全规模随机对照试验是可行的。

研究设计与样本

  • 预试验随机对照试验,比较葡萄糖-胰岛素-钾(GIK)与安慰剂在非糖尿病腹部盆腔大手术患者中的应用。
  • 248例合格患者中随机103例(平均年龄56岁,54%女性),GIK组50例、安慰剂组53例,随访至术后30天。

主要发现

  • 治疗完成率97%,无严重低血糖事件。
  • 围术期正常血糖(<125 mg/dL)GIK组42% vs 对照组27%(P<0.01)。
  • 高血糖(血糖>140 mg/dL)GIK组37% vs 对照组48%(P<0.05)。
  • 治疗性胰岛素使用GIK组26% vs 对照组45%,绝对风险降低(aRR)0.6(95%CI:0.4,0.9)。
  • 并发症GIK组12% vs 对照组21%(aRR 0.5,95%CI:0.2,1.5),置信区间宽。

临床怎么用

  • 在非糖尿病腹部盆腔大手术患者中,预防性GIK方案可行且未增加严重低血糖风险。
  • 该策略可改善围术期血糖控制并减少治疗性胰岛素使用,但临床结局获益需全规模随机对照试验验证。

局限性

  • 为预试验研究,样本量小,临床结局置信区间宽,无法得出确定性结论。
  • 研究仅纳入非糖尿病腹部盆腔大手术患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Determine the feasibility and proof-of-concept of using prophylactic insulin [glucose-insulin-potassium (GIK)] to improve outcomes in nondiabetic (NoDM) surgical patients. SUMMARY BACKGROUND DATA: Perioperative hyperglycemia increases the risk of morbidity/mortality, and insulin is used to treat it. Prevention of hyperglycemia with prophylactic insulin may be better than using treatment insulin alone, but feasibility issues need to be addressed before developing a full-scale randomized controlled trial (RCT). METHODS: A pilot RCT of GIK versus placebo among nondiabetic undergoing major abdominopelvic surgery. Feasibility (willingness to randomize, treatment completion) and clinical outcomes (glycemic control, neutrophil:lymphocyte ratio, and morbidity/mortality) were measured through 30 days. RESULTS: Of 248 eligible patients, 103 were randomized (mean age 56, 54% female) to GIK (n=50) or placebo (n=53). Treatment was completed in 97% without episodes of severe hypoglycemia. Perioperative euglycemia (<125 mg/dL) was more common in the GIK arm (42%) versus the control (27%) ( P <0.01). Hyperglycemia (BG >140 mg/dL) was less common in the GIK arm (37% vs. 48%, P <0.05), as was the use of treatment insulin (26% vs. 45%, Absolute Risk Reduction (aRR) 0.6 [95% CI: 0.4, 0.9]). The rise in neutrophil:lymphocyte ratio from preoperative to postoperative day 1 was lower in the GIK group versus placebo (Delta 0.5, 95% CI: -6.23 to 3.32). Fewer complications were noted in the GIK arm (12%) versus control (21%) (aRR 0.5 [95% CI: 0.2, 1.5]), albeit with wide CIs. CONCLUSIONS: Prophylactic insulin improves glycemic outcomes and may improve clinical outcomes, possibly in part through anti-inflammatory mechanisms. A full-scale RCT focused on morbidity/mortality endpoints is feasible and would address an important evidence gap.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Schnuck J, Jones IA, Schmicker RH, et al. The Use of Prophylactic Insulin in Surgical Patients Without Diabetes: A Pilot Randomized, Controlled Trial. Ann Surg. 2026. PMID: 42307115. doi:10.1097/SLA.0000000000007119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。